2. Tentori F., Wang M., Bieber B.A., et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin. J. Am. Soc. Nephrol. 2015;10(1):98–109.

3. Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 2011;6(4):913–21.

4. Chertow G.M., Block G.A., Correa-Rotter R., et al. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N. Engl. J. Med. 2012;367:2482–94.

5. Parfrey P.S., Block G.A., Correa-Rotter R., et al. Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clin. J. Am. Soc. Nephrol. 2016;11(3):539–46.

6. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008;359(6):584–92.

7. Behets G.J., Spasovski G., Sterling L.R., et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;87:846–56.

8. Subramanian R., Zhu X., Kerr S.J., et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide). Drug. Metab. Dispos. 2016;44(8):1319–31.

9. Kroenke M.A., Weeraratne D.K., Deng H., et al. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: method development challenges and anti-drug antibody clinical impact assessments. J. Immunol. Methods. 2017;445:37–44.

10. Wu L., Melhem M., Subramanian R., Wu B. Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. J. Pharmacokinet. Pharmacodyn. 2017;44(1):43–53.

11. Edson K.Z., Wu B.M., Iyer A., et al. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. Kidney Int. 2016;1(1):24–33.

12. Shen J., Xiao J., Pickthorn K., et al. A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. J. Clin. Pharmacol. 2014;54(10):1125–33.

13. Martin K.J., Bell G., Pickthorn K., et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol. Dial. Transplant. 2014;29(2):385–92.

14. Yokoyama K., Fukagawa M., Shigematsu T., et al. A single- and multipledose, multicenter study of etelcalcetide in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2017;2(4):634–44.

15. Bushinsky D.A., Block G.A., Martin K.J., et al. Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor. Am. J. Nephrol. 2015;42(5):379–88.

16. Bell G., Huang S., Martin K.J., Block G.A. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr. Med. Res. Opin. 2015;31(5):943–52.

17. Yokoyama K., Fukagawa M., Shigematsu T., et al. A 12-week doseescalating study of telcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin. Nephrol. 2017;88(8):68–78.

18. Block G.A., Bushinsky D.A., Cunningham J., et al. Effect of Etelcalcetide vs Placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism. Two Randomized Clinical Trials. JAMA. 2017;317(2):146–55.

19. Fukagawa M., Yokoyama K., Shigematsu T., et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol. Dial. Transplant. 2017;32(10):1723–30.

20. Shigematsu T., Fukagawa M., Yokoyama K., et al. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin. Exp. Nephrol. Epub. 2017 Aug 23.

21. Block G.A., Bushinsky D.A., Cheng S., et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156–64.

22. Flueckiger P., Pastan S., Goyal A., et al. Associations of ECG interval prolongations with mortality among ESRD patients evaluated for renal transplantation. Ann. Transplant. 2014;19:257–68.

23. Wheeler D.C., London G.M., Parfrey P.S., et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J. Am. Heart Assoc. 2014;3(6):e001363.